




Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to furnish information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
				Application Number	09/625,963
		Filing Date	July 26, 2000		
		First Named Inventor	Hans Josef Stauss		
		Group Art Unit	1644		
		Examiner Name	Decloux, A.		
Sheet	2	of	3	Attorney Docket Number	ICI 101

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AS	✓	AL-ODEIDI, et al., "Peptide and peptidomimetic libraries," <i>Molecular Biotechnology</i> 9:205-223 (1998).	
	✓	BEELEY, "Peptidomimetics and small-molecule drug design: towards improved bioavailability and <i>in vivo</i> stability," <i>TIBTECH</i> 12:213-216 (1994).	
	✓	BOTTGER, et al., "Molecular characterization of the hdm2-p53 interaction," <i>J Mol Biol</i> 269:744-756 (1997).	
	✓	CROSSLEY & ORKIN, "Phosphorylation of the Erythroid Transcription Factor GATA-1," <i>J Bio Chem</i> 269:16589-96 (1994).	
	✓	GAIGER, et al., "Immunity to WT1 in the animal model and in patients with acute myeloid leukemia," <i>Blood</i> 96(4):1480-89 (2000).	
	✓	GAO, et al., "Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specif for WT1," <i>Blood</i> 95:2198-2203 (2000).	
	✓	KIEBER-EMMONS, et al., "Therapeutic peptides and peptidomimetics," <i>Curr Opinion Biotechnol</i> 8:436-441 (1997).	
	✓	MEZIERE, et al., "In vivo helper cell response to retro-inverso peptidomimetics," <i>Journal of Immunology</i> 159:3230-37 (1997).	
	✓	MURALI & GREENE, "Structure-based design of immunologically active therapeutic peptides," <i>Immunologic Research</i> 17(1&2):163-169 (1998).	
	✓	NAKANISHI, et al., "Peptidomimetics of the immunoglobulin supergene family – a review," <i>Gene</i> 137:51-56 (1993).	

Examiner's Signature		Date Considered	10-29-01
----------------------	--	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	09/625,963
		Filing Date	July 26, 2000
		First Named Inventor	Hans Josef Stauss
		Group Art Unit	1644
		Examiner Name	Decloux, A.
		Attorney Docket Number	ICI 101
Sheet	3	of	3



RECEIVED

AUG 29 2001

TECH CENTER 1600/2900

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
an	-	OHMINAMI, et al., "HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T-lymphocyte clone specific for WT1 peptide," <i>Blood</i> 95:286-93 (2000).	
↓	<	OKA, et al., "Cancer immunotherapy targeting Wilms' Tumor Gene WT1 product," <i>J Immunol</i> 164:1873-80 (2000).	
↓	-	OKA, et al., "Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms tumor (WT1) product," <i>Immunogenetics</i> 51:99-107 (2000).	
↓	-	SADOVNIKOVA & STAUSS, "Peptide-specific cytotoxic T lymphocytes restricted by nonself major histocompatibility complex class I molecules: reagents for tumor immunotherapy," <i>Proc Natl Acad Sci USA</i> 93:13114-13118 (1996).	

Examiner's Signature		Date Considered
		10-27-01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.